trastuzumab,pertuzumab
roche
['trastuzumab,(-trastuzumab deruxtecan),(-trastuzumab-deruxtecan)', 'pertuzumab', 'breast', 'phergain', 'bcsm']
in the phergain trial, about 1 in 3 patients with her2+ breast cancer who were assigned to neoadjuvant trastuzumab and pertuzumab, with or without et, were able to skip chemotherapy safely. #asco23 #bcsm 
https://t.co/bi63MIVP5D is a resource offering oncology health care professionals practical information about the changing clinical landscape.